Antistax
Natural health product licensed in Canada
- Licence holder
- Opella Canada Inc.
- NPN or DIN-HM
- 80056447
- Status
- Inactive licence
- Licence date
- 11 December 2014
- Revision date
- 7 April 2021
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitis Vinifera Source : Feuille Extraction ratio : 4:1 Dry plant equivalent : 1,440 mg | 360 mg | Not calculated |
Non-medicinal ingredients
Crospovidone, Colloidal silicon dioxide, Stéarate de magnésium, Croscarmellose de sodium, Talc, Eau, Oxyde de fer (Fe2O3), Phosphate de calcium, dibasique, anhydre, Hypromellose, Cellulose microcristalline, Dioxyde de titane, Glyceryl tristearate
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Used in Herbal Medicine to help relieve symptoms related to chronic venous insufficiency (CVI), such as swollen legs, varicose veins, a feeling of heaviness, pain, tiredness, itching and tension. Helps reduce lower leg edema in chronic venous insufficiency (CVI). Helps improve lower leg blood flow in chronic venous insufficiency (CVI). Clinically proven to help provide symptomatic relief of chronic venous insufficiency (CVI). Source of/ Provides antioxidants. Antistax provides antioxidants that help fight/protect cells against oxidative effect by reducing oxidative cellular damage caused by free radicals.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80056447
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2021. Photograph the packaging to check whether it has changed. Photograph the packaging